Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>PK profile for EnaV and MMAE in the dose-escalation phase. Plasma/serum concentrations of (<b>A</b>) conjugated EnaV and (<b>B</b>) MMAE at Q3W. Dots indicate observed data; lines indicate mean data. LLOQ, lower limit of quantitation.</p>
में बचाया:
| मुख्य लेखक: | |
|---|---|
| अन्य लेखक: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| प्रकाशित: |
2025
|
| विषय: | |
| टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
| सारांश: | <p>PK profile for EnaV and MMAE in the dose-escalation phase. Plasma/serum concentrations of (<b>A</b>) conjugated EnaV and (<b>B</b>) MMAE at Q3W. Dots indicate observed data; lines indicate mean data. LLOQ, lower limit of quantitation.</p> |
|---|